Abstract:Dementia with Lewy body (DLB) is the second most common degenerative dementia after Alzheimer's disease. There is no therapeutic drug for DLB currently. It's urgent for us to understand the pathological mechanism of dementia mediated by α-synuclein, as the main component of Lewy body. Here, we found that the A53T α-synuclein transgenic mice showed decreased nesting behavior starting from the age of 1 month. The results in Morris water maze test suggested that the 6-month-old mice had learning memory deficits. Golgi staining indicated that the apical neuronal dendritic spines of hippocampal CA1 neurons were significantly reduced in 6-month-old homozygotes and heterozygotes, although MAP2 protein expression revealed no significant difference in the hippocampus among wild-type mice, homozygotes and heterozygotes. In vitro, we proved mutant A53T α-synuclein decreased the dendritic branches and dendrite spines on the embryonic mice hippocampal neurons. Furthermore, Ki67 immunofluorescence staining identified that the Ki67-positive cells of the hippocampal dentate gyrus and subventricular zone were significantly reduced in 6-month-old homozygotes and heterozygotes, compared with age-matched wild-type mice. Similarly, when 6-month-old mice were injected with BrdU for one day, the immunostaining results also confirmed that BrdU-positive cells were significantly reduced in homozygous and heterozygous mice. Lastly, we transfected primary embryonic hippocampal neural stem cells with lentivirus vector expressing A53T α-synuclein in vitro. Both BrdU staining and Western blotting showed that A53T α-synuclein significantly decreased the proliferation of embryonic neural stem cells. Taken together, these data suggest that A53T α-synuclein can induce adult neurogenesis impairment and cognitive dysfunction. The A53T α-synuclein transgenic mice may be used as an animal model for DLB. Promoting adult neurogenesis may be a promising approach to treat DLB pathogenesis.

DNA Damage Preceding Dopamine Neuron Degeneration in A53T Human Α-Synuclein Transgenic Mice.

Genomic DNA Levels of Mutant Alpha-Synuclein Correlate with Non-Motor Symptoms in an A53T Parkinson's Disease Mouse Model

Senescence and impaired DNA damage responses in alpha-synucleinopathy models

A53T α-synuclein induces neurogenesis impairment and cognitive dysfunction in line M83 transgenic mice and reduces the proliferation of embryonic neural stem cells

Conditional Expression Of Parkinson'S Disease-Related Mutant Alpha-Synuclein In The Midbrain Dopaminergic Neurons Causes Progressive Neurodegeneration And Degradation Of Transcription Factor Nuclear Receptor Related 1

Dopamine induces soluble α-synuclein oligomers and nigrostriatal degeneration

Cell senescence induced by toxic interaction between α-synuclein and iron precedes nigral dopaminergic neuron loss in a mouse model of Parkinson's disease

Non-Motor Parkinsonian Pathology In Aging A53t Alpha-Synuclein Mice Is Associated With Progressive Synucleinopathy And Altered Enzymatic Function

The A53T Mutation in α-Synuclein Enhances Proinflammatory Activation in Human Microglia Upon Inflammatory Stimulus

Dopaminergic neuron loss in mice due to increased levels of wild-type human α-Synuclein only takes place under conditions of accelerated aging

Mutant Alpha-Synuclein Causes Age-Dependent Neuropathology in Monkey Brain

Templating of Monomeric Alpha-Synuclein Induces Inflammation and SNpc Dopamine Neuron Death in a Genetic Mouse Model of Synucleinopathy.

Dopamine Auto-Oxidation Aggravates Non-Apoptotic Cell Death Induced by Over-Expression of Human A53t Mutant Alpha-Synuclein in Dopaminergic Pc12 Cells

Mitophagy Upregulation Occurs Early in the Neurodegenerative Process Mediated by α-Synuclein

Endoplasmic Reticulum Stress and Mitochondrial Cell Death Pathways Mediate A53T Mutant Alpha-Synuclein-induced Toxicity.

Decoding the Role of Familial Parkinson’s Disease-Related Genes in DNA Damage and Repair

Alpha-Synuclein Preformed Fibrils Induce Cellular Senescence in Parkinson’s Disease Models

Transgenic Mice Expressing Human Α-Synuclein 1-103 Fragment As a Novel Model of Parkinson's Disease.

Nuclear alpha-synuclein accelerates cell senescence and neurodegeneration

The Synergistic Effect Study of Lipopolysaccharide (LPS) and A53T-α-Synuclein: Intranasal LPS Exposure on the A53T-α-Synuclein Transgenic Mouse Model of Parkinson's Disease

Generation of G51D and 3D mice reveals decreased α-synuclein tetramer-monomer ratios promote Parkinson’s disease phenotypes